Last updated: 10/06/2020 14:10:05

A two-part study to compare a tablet and capsule formulation of GSK2838232 with and without food, and to assess the safety and drug levels of repeated once-daily doses of GSK2838232 without ritonavir

Request patient level data

GSK study ID

205820

See study documents

Clinicaltrials.gov ID

NCT03234036

See results summary

EudraCT ID

Not applicable

EU CT Number

Not applicable

Trial status

Study complete

Overview

Eligibility

Locations

Study documents

Results summary

Plain language summaries

Additional information

Trial overview

Official title: A Two Part Study to Assess i) the Relative Bioavailability and Food Effect of a Novel Tablet Formulation of Boosted-GSK2838232 Compared to Capsule and ii) the Safety and Pharmacokinetics of Repeated Once-Daily Doses of Non-boosted GSK2838232

Trial description: This study will be conducted in two Parts to confirm the acceptability/selection of a tablet formulation for future clinical development of GSK2838232. Part 1 of the study will assess single ritonavir (RTV)-boosted doses of a new tablet formulation given with food (containing approximately 30% fat) against the reference capsule formulation also given with food and then will assess the impact of fasted conditions on the tablet performance. In Part 2, non-boosted GSK2838232 will be given as once-daily tablet doses for 11 days in a separate group of subjects, assuming the tablet performance is considered acceptable from Part 1. Approximately 16 healthy subjects will be enrolled to provide at least 12 evaluable subjects through the three study periods in Part 1. 10 healthy subjects will be enrolled to provide at least 8 evaluable subjects through the single study period in Part 2. The maximum duration of study participation will be approximately 9 to 10 weeks for Part 1; and 8 to 9 weeks for Part 2.

Primary purpose:

Treatment

Trial design:

Crossover Assignment

Masking:

Double (Participant, Investigator)

Allocation:

Randomized

Primary outcomes:

Part 1: Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC [0-infinity]) following administration of GSK2838232 tablet and capsule formulation in fed state

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1 and 2 of Part 1

Part 1: Maximum observed concentration (Cmax) following administration of GSK2838232 tablet and capsule formulation in fed state

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1 and 2 of Part 1

Part 1: AUC (0-infinity) following administration of GSK2838232 tablet in fasted and fed state

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1

Part 1: Cmax following administration of GSK2838232 tablet in fasted and fed state

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1

Part 1: Time of occurrence of Cmax (Tmax) following administration of GSK2838232 tablet in fasted and fed state

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1

Part 2: Number of participants with serious adverse events (SAEs) and non-SAEs

Timeframe: Up to 25 days

Part 2: Number of participants with worst case hematology results to potential clinical importance (PCI) criteria

Timeframe: Up to 25 days

Part 2: Number of participants with worst case clinical chemistry results to PCI criteria

Timeframe: Up to 25 days

Part 2: Number of participants with worst case urinalysis results relative to normal range criteria

Timeframe: Up to 25 days

Part 2: Blood pressure at indicated time points

Timeframe: Day -1; Pre-dose, 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)

Part 2: Change from Baseline in blood pressure

Timeframe: Baseline (Day -1) and 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)

Part 2: Pulse rate at indicated time points

Timeframe: Day -1; Pre-dose, 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)

Part 2: Change from Baseline in Pulse rate

Timeframe: Baseline (Day -1) and 1, 4 hours on Day 1; 24 hours (Day 2); 48 hours (Day 3); 72 hours (Day 4), Days 5, 6, 7, 8, 9, 10; Pre-dose, 1, 4 , 24, 48, 72 hours on Day 11; Follow-up (Day 25)

Part 2: Number of participants with abnormal electrocardiogram (ECG) findings

Timeframe: Day -1; 1, 4, 12 hours on Day 1; Days 2, 3, 5, 8; 1, 4, 12, 24 Hours on Day 11; Follow-up (Day 25)

Part 2: Change from Baseline in mean heart rate values as ECG parameter

Timeframe: Baseline (Day -1) and 1, 4, 12 hours on Day 1; Days 2, 3 5, 8; Pre-dose, 1, 4, 12, 24 hours Day 11; Follow-up (Day 25)

Part 2: Change from Baseline in PR interval, QRS, QT interval, and QTcF interval as ECG parameters

Timeframe: Baseline (Day -1) and 1, 4, 12 hours on Day 1; Days 2, 3 5, 8; Pre-dose, 1, 4, 12, 24 hours Day 11; Follow-up (Day 25)

Part 2: Area under the plasma drug concentration time curve from pre-dose to the end of the dosing interval at steady state (AUC[0-tau]) following administration of non-boosted once-daily doses of GSK2838232 tablet in fed state

Timeframe: Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1; Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2

Part 2: Cmax following administration of non-boosted once-daily doses of GSK2838232 tablet in fed state

Part 2: Observed concentration at the end of the dosing interval (Ctau) following administration of non-boosted once-daily doses of GSK2838232 tablet in fed state

Part 2: Tmax following administration of non-boosted once-daily doses of GSK2838232 tablet in fed state

Part 2: Lag-time (tlag) following administration of non-boosted once-daily doses of GSK2838232 tablet in fed state on Day 1

Timeframe: Pre-dose, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours post-dose on Day 1 in Part 2

Part 2: AUC(0-infinity) following administration of non-boosted once-daily doses of GSK2838232 tablet in fed state on Day 11

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2

Part 2: Apparent terminal phase half-life (T1/2) following administration of non-boosted once-daily doses of GSK2838232 tablet in fed state on Day 11

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2

Part 2: Time of last quantifiable concentration (Tlast) following administration of non-boosted once-daily doses of GSK2838232 tablet in fed state on Day 11

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96 and 120 hours post-dose on Day 11 in Part 2

Secondary outcomes:

Part 1: Number of participants with SAEs and non-SAEs

Timeframe: Up to 60 days

Part 1: Number of participants with worst case hematology results to PCI criteria

Timeframe: Up to 60 days

Part 1: Number of participants with worst case clinical chemistry results to PCI criteria

Timeframe: Up to 60 days

Part 1: Number of participants with worst case urinalysis results relative to normal range criteria

Timeframe: Up to 60 days

Part 1: Blood pressure at indicated time points

Timeframe: Day -2; Day -1; Pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1

Part 1: Change from Baseline in blood pressure

Timeframe: Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1

Part 1: Pulse rate at indicated time points

Timeframe: Day -2; Day -1; Pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1

Part 1: Change from Baseline in Pulse rate

Timeframe: Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 Hours on Day 1

Part 1: Number of participants with abnormal ECG findings

Timeframe: Day -2, Day -1; 1, 2, 4, 6, 8, , 12, 24, 48, 72 hours on Day 1

Part 1: Change from Baseline in mean heart rate values as ECG parameter

Timeframe: Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 hours on Day 1

Part 1: Change from Baseline in PR interval, QRS, QT interval, and QTcF interval as ECG parameters

Timeframe: Baseline (Day -1) and 1, 2, 4, 6, 8, 12, 24, 48, 72 hours on Day 1

Part 1: Tlag following administration of GSK2838232 tablet and capsule formulation in fed state and tablet formulation in fasted state

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1

Part 1: Tmax following administration of GSK2838232 tablet and capsule formulation in fed state and tablet formulation in fasted state

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1

Part 1: T1/2 following administration of GSK2838232 tablet and capsule formulation in fed state and tablet formulation in fasted state

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1

Part 1: Tlast following administration of GSK2838232 tablet and capsule formulation in fed state and tablet formulation in fasted state

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1

Part 1: Plasma drug concentration at 24 hours (C24) following administration of GSK2838232 tablet and capsule formulation in fed state and tablet formulation in fasted state

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1

Part 1: AUC(0-t) following administration of GSK2838232 tablet and capsule formulation in fed state and tablet formulation in fasted state

Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post-dose in treatment periods 1, 2 and 3 of Part 1

Part 2: Slope of pre-dose concentration of GSK2838232 administered as non-boosted once-daily doses of a tablet formulation to assess achievement of steady state

Timeframe: Pre-dose on Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10 and Day 11 in Part 2

Part 2: Accumulation ratio calculated from AUC(0-tau) following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation

Part 2: Accumulation ratio calculated from Cmax following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation

Part 2: Accumulation ratio calculated from Ctau following administration of GSK2838232 as non-boosted once-daily doses of a tablet formulation

Interventions:

Drug: GSK2838232 100 mg tablet

Drug: GSK2838232 50 mg capsule

Drug: Ritonavir 100 mg tablets

Drug: Placebo for GSK2838232 tablets

Enrollment:

Primary completion date:

2017-10-11

Observational study model:

Not applicable

Time perspective:

Not applicable

Clinical publications:

Mark Johnson, Roxanne C. Jewell, Jianjun Gan, Etienne Dumont, Olivia Burns, and Brian A. Johns. Phase I study to assess relative bioavailability, food effect, and safety of a tablet formulation of GSK28838232, a novel HIV maturation inhibitor in healthy participants after single and repeated doses. Clin Pharmacol Drug Devel. 2020 DOI: 10.1002/cpdd.820

Medical condition

Infection, Human Immunodeficiency Virus

Product

GSK2838232, ritonavir

Collaborators

Not applicable

Study date(s)

August 2017 to November 2017

Type

Interventional

Phase

Participation criteria

Sex

Female & Male

Age

18 - 55 years

Accepts healthy volunteers

Yes

Between 18 and 55 years of age inclusive, at the time of signing the informed consent.
Healthy as determined by the Investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.

ALT >1.5 times upper limit of normal (ULN)
Bilirubin >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent).

Inclusion and exclusion criteria

Inclusion criteria:

Between 18 and 55 years of age inclusive, at the time of signing the informed consent.
Healthy as determined by the Investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, and outside the reference range for the population being studied, may be included only if the Investigator in consultation with the medical monitor, if required, agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
A creatinine clearance (CLcr) > 80 milliliter per minute (mL/min) as determined by Cockcroft-Gault equation: CLcr = (140 minus age) multiplied by weight divided by (72 multiplied by serum creatinine) (times 0.85 if female) where age is in years, weight in kilogram (kg), and serum creatinine is in units of milligram per deciliter (mg/dL).
Body weight >=50.0 kg (110 pounds [lbs.]) for men and >=45.0 kg (99 lbs) for women and body mass index (BMI) within the range 18.5 to 31.0 kg/meter (m)^2 (inclusive).
Males or females.

A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotrophin [hCG] test), not lactating, and of non-reproductive potential which is defined as: Reproductive potential: There is no definitive drug-drug interaction (DDI) information with GSK2838232 and an interaction with oral contraceptives is possible, so other (barrier, inter-uterine device etc.) methods of contraception will be required. Females of reproductive potential may only be enrolled if they are using two forms of complementary contraception, which must include at least one barrier method. They will be counseled on safer sex practices. Fertile females, who have an established, long-term lifestyle of sexual abstinence, or only same sex partners, require no other means of birth control. Non-reproductive potential:

Pre-menopausal females with one of the following: Documented tubal ligation; documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; hysterectomy; documented Bilateral Oophorectomy.
Postmenopausal defined as 12 months of spontaneous amenorrhea in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause. Females on hormone replacement therapy (HRT) must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.

Male subjects with female partners of child bearing potential must comply with the following contraception requirements from the time of first dose of study medication until one week after the last dose of study medication.

Vasectomy with documentation of azoospermia.
Male condom plus partner use of one of the contraceptive options below: Contraceptive subdermal implant with a <1 percent rate of failure per year; intrauterine device or intrauterine system with a <1 percent rate of failure per year; oral contraceptive, either combined or progestogen alone or injectable progestogen; contraceptive vaginal ring; percutaneous contraceptive patches.

Capable of giving signed informed consent.

Exclusion criteria:

ALT >1.5 times upper limit of normal (ULN)
Bilirubin >1.5 times ULN (isolated bilirubin >1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent).
Current or chronic history of liver disease, or known hepatic or biliary abnormalities.
Subjects who have asthma or a history of asthma.
Medical history of cardiac arrhythmias or cardiac disease or a family or personal history of long QT syndrome.
Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John’s Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GlaxoSmithKline medical monitor, the medication will not interfere with the study procedures or compromise participant safety.

History of regular alcohol consumption (within 6 months prior to screening or unable to refrain from alcohol use from 5 days prior to admission through the last blood sample collected) defined as:

For United States sites: an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 gram of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.

Regular use of tobacco- or nicotine- containing products within 6 months prior to screening. Unable to refrain from smoking from the Screening Visit through the last blood sample collected. As confirmed by a urine cotinine test.
History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
Presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C virus (HCV) test result at screening or within 3 months prior to first dose of study treatment.
Screening or Baseline cardiac troponin I greater than the 99 percent cutoff (>0.045 nanogram [ng]/mL by the Dimension Vista cTnI assay) for a given assay.
A positive pre-study drug/alcohol screen.
A positive test for human immunodeficiency virus (HIV) antibody.
Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56 days.
The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
Exposure to more than four new chemical entities within 12 months prior to the first dosing day.

Exclusion Criteria for 24-hour Screening Holter:

Any symptomatic arrhythmia (except isolated extra systoles).
Sustained cardiac arrhythmias (such as atrial fibrillation or flutter, supraventricular tachycardia (>= 10 consecutive beats), complete heart block).
Non-sustained or sustained ventricular tachycardia (defined as >=3 consecutive ventricular ectopic beats).
Any conduction abnormality (including but not specific to left or right incomplete or complete bundle branch block, atrioventricular (AV) block [2nd degree or higher], Wolff Parkinson White (WPW) syndrome etc.).
Sinus Pauses >3 seconds.
300 or more supraventricular ectopic beats in 24 hours.
250 or more ventricular ectopic beats in 24 hours.

Any clinically significant abnormal echocardiogram finding.

Exclusion criteria for screening ECG (a single repeat is allowed for eligibility determination):

Heart rate <45 or >100 beats per minute (bpm) for males; <50 or >100 bpm for females
PR interval <120 or >220 milliseconds (msec)
QRS duration <70 or >120 msec
QTc interval (Fridericia’s) >450 msec
Evidence of previous myocardial infarction (does not include ST segment changes associated with re-polarization).
Any conduction abnormality (including but not specific to left or right complete bundle branch block, AV block [2nd degree or higher], WPW syndrome).
Sinus Pauses >3 seconds.
Any significant arrhythmia which, in the opinion of the Investigator or GSK medical monitor, will interfere with the safety for the individual subject.
Non-sustained or sustained ventricular tachycardia (>=3 consecutive ventricular ectopic beats).

Trial location(s)

Location

Status

Location

GSK Investigational Site

Baltimore, Maryland, United States, 21225

Status

Study Complete

Study documents

Clinical study report

Available language(s): English

Download document(s)

Protocol

Available language(s): English

Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Results posted on ClinicalTrials.gov

Recruitment status

Study complete

Actual primary completion date

2017-10-11

Actual study completion date

2017-10-11

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information

Not applicable

Participate in clinical trial

Access to clinical trial data by researchers

Visit website